Fulgent Genetics Inc - Asset Resilience Ratio
Fulgent Genetics Inc (FLGT) has an Asset Resilience Ratio of 21.87% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Fulgent Genetics Inc's Asset Resilience Ratio has changed over time. Check FLGT strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Fulgent Genetics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see FLGT market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $252.90 Million | 21.87% |
| Total Liquid Assets | $252.90 Million | 21.87% |
Asset Resilience Insights
- Good Liquidity Position: Fulgent Genetics Inc maintains a healthy 21.87% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Fulgent Genetics Inc Industry Peers by Asset Resilience Ratio
Compare Fulgent Genetics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Cowealth Medical China Co.Ltd.
SHG:603122 |
Diagnostics & Research | 2.25% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Chemclin Diagnostics Co. Ltd. A
SHG:688468 |
Diagnostics & Research | 15.34% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
SCOPE FLUIDICS SA ZY-10
F:S84 |
Diagnostics & Research | 32.55% |
|
Avricore Health Inc
V:AVCR |
Diagnostics & Research | 1.78% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
Annual Asset Resilience Ratio for Fulgent Genetics Inc (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Fulgent Genetics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 23.56% | $285.88 Million | $1.21 Billion | +6.92pp |
| 2024-12-31 | 16.64% | $202.96 Million | $1.22 Billion | -9.81pp |
| 2023-12-31 | 26.44% | $326.68 Million | $1.24 Billion | -5.79pp |
| 2022-12-31 | 32.23% | $446.73 Million | $1.39 Billion | +9.90pp |
| 2021-12-31 | 22.34% | $285.61 Million | $1.28 Billion | -7.92pp |
| 2020-12-31 | 30.26% | $211.94 Million | $700.46 Million | +11.89pp |
| 2019-12-31 | 18.37% | $16.30 Million | $88.76 Million | -37.40pp |
| 2018-12-31 | 55.77% | $30.68 Million | $55.02 Million | -5.47pp |
| 2017-12-31 | 61.24% | $34.88 Million | $56.95 Million | -5.21pp |
| 2016-12-31 | 66.45% | $38.57 Million | $58.04 Million | -- |
About Fulgent Genetics Inc
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pa… Read more